Arie Belldegrun, MD, FACS

Chairman & Partner

Dr. Belldegrun is the Chairman and a Partner of Two River. He is also the Chairman, President and Chief Executive Officer of Kite Pharma (KITE), which he co-founded. In 1996, Dr. Belldegrun founded Agensys, Inc. and served as its founding Chairman and a member of the board of directors until 2007 when it was acquired by Astellas Pharma Inc. Dr. Belldegrun was also the Founding Vice-Chairman of the board of directors and Chairman of the scientific advisory board of Cougar Biotechnology, Inc., a biotechnology company, which was acquired by Johnson & Johnson in 2009. Dr. Belldegrun also serves as Chairman of both Arno Therapeutics (ARNI.OB) and several privately held companies, including UroGen Pharma and Cell Design Labs. He is also a member of the Parker Institute for Cancer Immunotherapy’s Strategic Advisory Group.

Dr. Belldegrun is certified by the American Board of Urology, and is a Fellow of the American College of Surgeons and the American Association of Genitourinary Surgeons. He is Professor of Urology, holds the Roy and Carol Doumani Chair in Urologic Oncology, and Director of the Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. Prior to joining UCLA in October of 1988, he was a Research Fellow at the NCI/NIH in surgical oncology and immunotherapy from July 1985 to August 1988 under Dr. Steven A. Rosenberg. Dr. Belldegrun completed his M.D. at the Hebrew University Hadassah Medical School in Jerusalem, his post graduate studies in Immunology at the Weizmann Institute of Science and his residency in Urologic Surgery at Harvard Medical School.